Deutsche Bank Starts Jazz Pharmaceuticals (JAZZ) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Buckingham Research Starts Jazz Pharmaceuticals (JAZZ) at Buy
July 23, 2014 8:32 AM EDTBuckingham Research initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $215.00.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $145.87 yesterday.
... MoreJazz (JAZZ)/ Concert (CNCE) Initiate First Phase 1 Clinical Trial of JZP-386
July 21, 2014 4:26 PM EDTJazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybatethe active ingredient in Xyrem® (sodium oxybate) oral solution.
The Phase 1 clinical trial is designed to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386, and includes Xyrem as an active control. The study is expected to enroll up to 28... More
